Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.

ABSTRACT:

Background & aims

The approval of all-oral direct-acting antiviral (DAA) regimens for the treatment of hepatitis C virus (HCV) has led to the expansion of therapy to include patients with cirrhosis who have hepatocellular carcinoma (HCC). Data on the use of DAAs in HCV+ patients with HCC is limited. The aim of this study was to assess the efficacy of all-oral-DAA regimens in HCV+ cirrhotic patients who have or had HCC compared to those without HCC.

Methods

A retrospective cohort study was conducted on all cirrhotic patients who were treated for HCV with DAAs at our institution between January 2014 and November 2015.

Results

A total of 421 HCV+ patients with cirrhosis were identified, of whom 33% had active or a history of HCC. Failure to achieve sustained virologic re

SUBMITTER: Prenner SB 

PROVIDER: S-EPMC5776681 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature